Vir Biotechnology, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Vir closed a global strategic collaboration with Astellas worth $240M upfront plus $75M equity investment to advance VIR-5500 (PSMA-targeted T-cell engager) for prostate cancer. Phase 2 SOLSTICE data showed elebsiran/tobevibart achieved undetectable HDV RNA in 88% of CHD patients at Week 96 (28/32 ITT); Phase 3 ECLIPSE 1 topline expected Q4 2026. Q2 2026: $238.9M revenue (license/collaboration), $80.1M net income ($0.47/share diluted), $1.01B cash, and 169.2M shares outstanding (+29.7M vs. Dec 2025).
Why this rating
Major partnership ($240M ≈ 35% of market cap) de-risks oncology pipeline; strong CHD Phase 2 validates path to Phase 3. Non-recurring revenue inflates Q2 results but extends runway to H2 2028. Moderate positive catalysts ahead.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.